Skip to main content
Erschienen in: Digestive Diseases and Sciences 6/2017

11.04.2017 | Original Article

Medical Therapies for Stricturing Crohn’s Disease: Efficacy and Cross-Sectional Imaging Predictors of Therapeutic Failure

verfasst von: Cécile Campos, Antoine Perrey, Céline Lambert, Bruno Pereira, Marion Goutte, Anne Dubois, Felix Goutorbe, Michel Dapoigny, Gilles Bommelaer, Constance Hordonneau, Anthony Buisson

Erschienen in: Digestive Diseases and Sciences | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Medical therapy efficacy remains controversial in stricturing Crohn’s disease. Cross-sectional imaging, especially magnetic resonance imaging, has been suggested as very helpful to guide therapeutic decision making.

Aim

To assess efficacy and predictors of therapeutic failure in patients receiving medical treatments for stricturing Crohn’s disease.

Methods

In this retrospective study, therapeutic failure was defined as symptomatic stricture leading to surgical or endoscopic therapeutics, hospitalization, treatment discontinuation or additional therapy and short-term clinical response as clinical improvement assessed by two physicians. The 55 cross-sectional imaging examinations (33 magnetic resonance imaging and 22 CT scan) before starting medical therapy were analyzed independently by two radiologists. Results were expressed as hazard ratio (HR) or odds ratio (OR) with 95% confidence intervals (95% CI).

Results

Among 84 patients, therapeutic failure rate within 60 months was 66.6%. In multivariate analysis, Crohn’s disease diagnosis after 40 years old (HR 3.9, 95% CI [1.37–11.2], p = 0.011), small stricture luminal diameter (HR 1.34, 95% CI [1.01–1.80], p = 0.046), increased stricture wall thickness (HR 1.23, 95% CI [1.04–1.46], p = 0.013) and fistula with abscess (HR 5.63, 95% CI [1.64–19.35], p = 0.006) were associated with therapeutic failure, while anti-TNF combotherapy (HR 0.17, 95% CI [0.40–0.71], p = 0.015) prevented it. Considering 108 therapeutic sequences, the short-term clinical response rate was 65.7%. In multivariate analysis, male gender (OR 0.15, 95% CI [0.03–0.64], p = 0.011), fistula with abscess (OR 0.09, 95% CI [0.01–0.77], p = 0.028) and comb sign (OR 0.23, 95% CI [0.005–0.97], p = 0.047) were associated with short-term clinical failure.

Conclusion

Anti-TNF combotherapy seemed to prevent therapeutic failure, and cross-sectional imaging should be systematically performed to help medical management in stricturing Crohn’s disease.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis. 2010;16:15–22. doi:10.1002/ibd.21010.CrossRefPubMed Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis. 2010;16:15–22. doi:10.​1002/​ibd.​21010.CrossRefPubMed
3.
Zurück zum Zitat Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012;61:241–247. doi:10.1136/gutjnl-2011-300049.CrossRefPubMed Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012;61:241–247. doi:10.​1136/​gutjnl-2011-300049.CrossRefPubMed
6.
Zurück zum Zitat Sjöberg D, Holmström T, Larsson M, et al. Incidence and clinical course of Crohn’s disease during the first year—results from the IBD Cohort of the Uppsala Region (ICURE) of Sweden 2005–2009. J Crohns Colitis. 2014;8:215–222. doi:10.1016/j.crohns.2013.08.009.CrossRefPubMed Sjöberg D, Holmström T, Larsson M, et al. Incidence and clinical course of Crohn’s disease during the first year—results from the IBD Cohort of the Uppsala Region (ICURE) of Sweden 2005–2009. J Crohns Colitis. 2014;8:215–222. doi:10.​1016/​j.​crohns.​2013.​08.​009.CrossRefPubMed
7.
9.
Zurück zum Zitat Zappa M, Stefanescu C, Cazals-Hatem D, et al. Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohn’s disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis. 2011;17:984–993. doi:10.1002/ibd.21414.CrossRefPubMed Zappa M, Stefanescu C, Cazals-Hatem D, et al. Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohn’s disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis. 2011;17:984–993. doi:10.​1002/​ibd.​21414.CrossRefPubMed
10.
Zurück zum Zitat Rimola J, Planell N, Rodríguez S, et al. Characterization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging. Am J Gastroenterol. 2015;. doi:10.1038/ajg.2014.424. Rimola J, Planell N, Rodríguez S, et al. Characterization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging. Am J Gastroenterol. 2015;. doi:10.​1038/​ajg.​2014.​424.
11.
Zurück zum Zitat Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.CrossRefPubMed Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.CrossRefPubMed
14.
Zurück zum Zitat Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232–1239.CrossRefPubMedPubMedCentral Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232–1239.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterol. 2007;132:52–65.CrossRef Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterol. 2007;132:52–65.CrossRef
16.
Zurück zum Zitat Louis E, Boverie J, Dewit O, et al. Treatment of small bowel subocclusive Crohn’s disease with infliximab: an open pilot study. Acta Gastro-Enterol Belg. 2007;70:15–19. Louis E, Boverie J, Dewit O, et al. Treatment of small bowel subocclusive Crohn’s disease with infliximab: an open pilot study. Acta Gastro-Enterol Belg. 2007;70:15–19.
18.
19.
Zurück zum Zitat Condino G, Calabrese E, Zorzi F, et al. Anti-TNF-alpha treatments and obstructive symptoms in Crohn’s disease: a prospective study. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2013;45:258–262. doi:10.1016/j.dld.2012.10.009. Condino G, Calabrese E, Zorzi F, et al. Anti-TNF-alpha treatments and obstructive symptoms in Crohn’s disease: a prospective study. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2013;45:258–262. doi:10.​1016/​j.​dld.​2012.​10.​009.
20.
Zurück zum Zitat Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4:621–630. doi:10.1016/j.cgh.2006.03.002. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4:621–630. doi:10.​1016/​j.​cgh.​2006.​03.​002.
22.
Zurück zum Zitat Pallotta N, Barberani F, Hassan N-A, Guagnozzi D, Vincoli G, Corazziari E. Effect of infliximab on small bowel stenoses in patients with Crohn’s disease. World J Gastroenterol. 2008;14:1885–1890.CrossRefPubMedPubMedCentral Pallotta N, Barberani F, Hassan N-A, Guagnozzi D, Vincoli G, Corazziari E. Effect of infliximab on small bowel stenoses in patients with Crohn’s disease. World J Gastroenterol. 2008;14:1885–1890.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Bouhnik Y, Carbonnel F, Laharie D, et al. 287 Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort study (CREOLE). Gastroenterology. 2015;148:S-62. doi:10.1016/S0016-5085(15)30216-X.CrossRef Bouhnik Y, Carbonnel F, Laharie D, et al. 287 Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort study (CREOLE). Gastroenterology. 2015;148:S-62. doi:10.​1016/​S0016-5085(15)30216-X.CrossRef
24.
Zurück zum Zitat Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2. (discussion 6-19).CrossRefPubMed Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2. (discussion 6-19).CrossRefPubMed
25.
Zurück zum Zitat Buisson A, Filippi J, Amiot A, et al. Su1229 Definitions of the endoscopic lesions in Crohn’s disease: reproductibility study and GETAID expert consensus. Gastroenterology. 2015;148:S-445. doi:10.1016/S0016-5085(15)31500-6. Buisson A, Filippi J, Amiot A, et al. Su1229 Definitions of the endoscopic lesions in Crohn’s disease: reproductibility study and GETAID expert consensus. Gastroenterology. 2015;148:S-445. doi:10.​1016/​S0016-5085(15)31500-6.
26.
Zurück zum Zitat Buisson A, Joubert A, Montoriol P-F, et al. Diffusion-weighted magnetic resonance imaging for detecting and assessing ileal inflammation in Crohn’s disease. Aliment Pharmacol Ther. 2013;37:537–545. doi:10.1111/apt.12201.CrossRefPubMed Buisson A, Joubert A, Montoriol P-F, et al. Diffusion-weighted magnetic resonance imaging for detecting and assessing ileal inflammation in Crohn’s disease. Aliment Pharmacol Ther. 2013;37:537–545. doi:10.​1111/​apt.​12201.CrossRefPubMed
27.
Zurück zum Zitat Hordonneau C, Buisson A, Scanzi J, et al. Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn’s disease: validation of quantitative index of activity. Am J Gastroenterol. 2014;109:89–98. doi:10.1038/ajg.2013.385.CrossRefPubMed Hordonneau C, Buisson A, Scanzi J, et al. Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn’s disease: validation of quantitative index of activity. Am J Gastroenterol. 2014;109:89–98. doi:10.​1038/​ajg.​2013.​385.CrossRefPubMed
28.
Zurück zum Zitat Buisson A, Hordonneau C, Goutte M, et al. Diffusion-weighted magnetic resonance enterocolonography in predicting remission after anti-TNF induction therapy in Crohn’s disease. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2015;. doi:10.1016/j.dld.2015.10.019. Buisson A, Hordonneau C, Goutte M, et al. Diffusion-weighted magnetic resonance enterocolonography in predicting remission after anti-TNF induction therapy in Crohn’s disease. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2015;. doi:10.​1016/​j.​dld.​2015.​10.​019.
29.
Zurück zum Zitat Buisson A, Hordonneau C, Goutte M, Boyer L, Pereira B, Bommelaer G. Diffusion-weighted magnetic resonance imaging is effective to detect ileocolonic ulcerations in Crohn’s disease. Aliment Pharmacol Ther. 2015;. doi:10.1111/apt.13287.PubMed Buisson A, Hordonneau C, Goutte M, Boyer L, Pereira B, Bommelaer G. Diffusion-weighted magnetic resonance imaging is effective to detect ileocolonic ulcerations in Crohn’s disease. Aliment Pharmacol Ther. 2015;. doi:10.​1111/​apt.​13287.PubMed
30.
Zurück zum Zitat Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–381. doi:10.1016/j.jbi.2008.08.010.CrossRefPubMed Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–381. doi:10.​1016/​j.​jbi.​2008.​08.​010.CrossRefPubMed
31.
Zurück zum Zitat Bossuyt P, Debeuckelaere C, Billiet T, et al. Su1814 The need for surgery in stricturing ileal CD Is linked to clinical and imaging factors but independent of NOD2 genotype. Gastroenterology. 2016;150:S560. doi:10.1016/S0016-5085(16)31913-8.CrossRef Bossuyt P, Debeuckelaere C, Billiet T, et al. Su1814 The need for surgery in stricturing ileal CD Is linked to clinical and imaging factors but independent of NOD2 genotype. Gastroenterology. 2016;150:S560. doi:10.​1016/​S0016-5085(16)31913-8.CrossRef
Metadaten
Titel
Medical Therapies for Stricturing Crohn’s Disease: Efficacy and Cross-Sectional Imaging Predictors of Therapeutic Failure
verfasst von
Cécile Campos
Antoine Perrey
Céline Lambert
Bruno Pereira
Marion Goutte
Anne Dubois
Felix Goutorbe
Michel Dapoigny
Gilles Bommelaer
Constance Hordonneau
Anthony Buisson
Publikationsdatum
11.04.2017
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 6/2017
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4572-4

Weitere Artikel der Ausgabe 6/2017

Digestive Diseases and Sciences 6/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.